Document is current
Any future updates will be listed below
-
Authors
Ogita, Mami https://orcid.org/0000-0002-1539-4298
Sawayanagi, Subaru
Jinnouchi, Haruka
Yoshimura, Michio
Yamauchi, Chikako
Sanuki, Naoko
Hamamoto, Yasushi
Hirata, Kimiko
Kawamura, Mariko
Yamamoto, Yutaka
Saji, Shigehira
Toyama, Tatsuya
-
Funding
Funding for this research was provided by:
Japanese Breast Cancer Society
The University of Tokyo
- License Information
-
More Information
Article History
Received: 8 July 2025
Accepted: 16 September 2025
First Online: 25 September 2025
Declarations
:
: YY received a research grant from Chugai, AstraZeneca, MSD, Daiichi-Sankyo, Gilead Sciences, Ono, and Novartis and honoraria from AstraZeneca, Chugai, Kyowa-Kirin, Novartis, Lilly, Pfizer, Daiichi-Sankyo, Gilead Sciences, Taiho, Eisai, Takeda, MSD, Sysmex, and Exact Science. He is an advisory board member of AstraZeneca, MSD, Pfizer, and Daiichi Sankyo. SS received research grants from Taiho, Eisai, Chugai, Takeda, MSD, Astra Zeneca, Daiichi Sankyo, Gilead, Eli Lilly, Sanofi, and honoraria from Chugai, Kyowa Kirin, MSD, Novartis, Eisai, Takeda, Daiichi Sankyo, Eli Lilly, Astra Zeneca, Pfizer, Taiho, Ono, Nipponkayaku, Gilead, and Exact Sciences. He is an advisory board member of Chugai/Roche, Astra Zeneca, Eli Lilly, Pfizer, Kyowa Kirin, Daiichi Sankyo, and MSD and an executive board member of JBCRG, JBCS, JSMO, and BIG. TT received honoraria from Chugai, Daiichi Sankyo, Pfizer, MSD, Lilly, Novartis, and Taiho. H declare no conflict of interest. The authors declare no conflicts of interest.
: This article does not contain any studies with human participants or animals performed by any of the authors.
: Not applicable.
